SpartaLabs
0
SpartaLabs Research · June 17, 2026

Retatrutide: A Research Overview

A research-library overview of retatrutide (LY3437943) — chemistry, pharmacological classification as a triple receptor agonist, and regulatory status as an investigational compound. Educational reference.

retatrutideglp-1gipglucagontriple-agonistincretin

Introduction

Retatrutide (development code LY3437943) is a synthetic acylated peptide compound developed by Eli Lilly and Company, classified in the scientific literature as a simultaneous agonist at three distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor (GIPR), the glucagon-like peptide-1 receptor (GLP-1R), and the glucagon receptor (GCGR). This pharmacological profile — engaging all three receptor systems with a single synthetic molecule — represents a step beyond the dual incretin receptor agonism realized clinically with tirzepatide, and has generated substantial attention in the cardiometabolic research community. This article provides an educational reference overview of retatrutide's chemical identity, pharmacological classification, discovery history, and regulatory development status, based on published primary literature and official clinical trial registrations.

Background

The incretin system — composed of intestinally derived peptide hormones that modulate insulin secretion in a glucose-dependent manner — has been a productive focus of cardiometabolic research for several decades. Two incretin hormones, GIP and GLP-1, were characterized through independent lines of research beginning in the 1970s and 1980s. A third pancreatic hormone, glucagon, secreted by islet alpha cells, regulates hepatic glucose output and has been investigated as a target for energy-balance modulation.

Dual incretin receptor agonism was first realized clinically with tirzepatide (LY3298176), a combined GIP/GLP-1 receptor agonist approved by the FDA in 2022. Retatrutide extends this line of inquiry: the addition of glucagon receptor agonism to dual incretin engagement in a single synthetic molecule. The discovery and preclinical characterization of LY3437943 were first reported by Coskun, Urva, Roell, and colleagues in 2022, describing the compound's design rationale, receptor binding profile, preclinical metabolic data, and phase 1 single-ascending-dose clinical findings [1].

Chemistry and Structure

Retatrutide is an acylated synthetic peptide. Its primary sequence was derived from the native human GIP peptide backbone, a structural approach also used in the design of tirzepatide. Retatrutide incorporates sequence modifications and a fatty acid acyl chain attached via a linker to confer albumin-binding properties and extend plasma half-life, enabling extended-interval dosing consistent with other approved incretin agents.

In vitro pharmacological characterization reported by Coskun and colleagues described retatrutide's potency profile relative to the corresponding endogenous hormones. The molecule was reported to display substantially greater potency at the GIPR compared with native GIP, while demonstrating agonist activity at the GCGR and GLP-1R at subphysiological relative potencies compared with native glucagon and GLP-1, respectively [1]. The structural basis for retatrutide's simultaneous engagement of all three receptor complexes was characterized in a 2024 cryo-electron microscopy study published in Cell Discovery, which identified the molecular determinants governing each receptor interaction [2].

Retatrutide's pharmacokinetic profile in the first-in-human phase 1 study was reported to support extended-interval dosing, consistent with other acylated incretin peptides [1].

Pharmacological Classification

Retatrutide is classified in the scientific literature as a triple GIP receptor, GLP-1 receptor, and glucagon receptor agonist — also referred to as a "triagonist" or "triple incretin receptor agonist." This pharmacological classification distinguishes it from selective GLP-1 receptor agonists (such as semaglutide or liraglutide) and from dual GIP/GLP-1 receptor agonists (such as tirzepatide). Further detail on retatrutide's receptor pharmacology is covered in the retatrutide mechanism of action article.

The addition of glucagon receptor agonism is proposed in the preclinical literature as a mechanism by which energy expenditure may be modulated independently of the appetite and glucose-regulatory effects attributed to GIP and GLP-1 receptor co-agonism. Coskun and colleagues reported in preclinical models that body weight reductions in obese mice were augmented by GCGR-mediated increases in energy expenditure added to GIPR- and GLP-1R-driven reductions in caloric intake [1]. The relative contribution of each receptor to observed effects in human clinical settings has been an area of active investigation across subsequent phase 1 and phase 2 trials.

Discovery History

The scientific lineage of retatrutide traces through decades of research on each of the three receptor systems it targets. GIP was characterized as an incretin hormone in the early 1970s. GLP-1 was identified as biologically active in the 1980s through work on the proglucagon gene by Habener, Mojsov, Drucker, Holst, and colleagues. Glucagon was isolated and characterized in the 1950s by Staub, Sinn, and Behrens.

The hypothesis that simultaneous engagement of GIP, GLP-1, and glucagon receptors in a single synthetic molecule could produce metabolic effects beyond those achievable by dual incretin agonism drove a research program at Eli Lilly that extended from their earlier tirzepatide work. The compound designated LY3437943 was the product of this program. Its first public description in the peer-reviewed literature appeared in Coskun et al., 2022, published in Cell Metabolism [1], followed by phase 1b and phase 2 publications in The Lancet and the New England Journal of Medicine during 2022 and 2023.

Regulatory Status

Retatrutide (LY3437943) is an investigational new drug in active clinical development by Eli Lilly and Company, with phase 3 trials registered under the TRIUMPH and TRANSCEND program names. Phase 2 clinical data in two populations — adults with obesity or overweight, and adults with type 2 diabetes — were published in the peer-reviewed literature in 2023 [3,4]. Phase 3 trials include NCT05929066 (obesity/overweight without type 2 diabetes), NCT05929079 (obesity/overweight with type 2 diabetes), and NCT06354660 (TRANSCEND-T2D-1, type 2 diabetes managed by diet and exercise) [5,6,7]. The TRANSCEND-T2D-1 trial reported initial phase 3 results in The Lancet in 2026 [8].

The compound has not received regulatory approval from the FDA, the European Medicines Agency, or any comparable regulatory body for any therapeutic indication as of this writing. Research-use-only contexts are governed by applicable institutional and regulatory frameworks distinct from approved pharmaceutical indications. Research-grade retatrutide from SpartaLabs is supplied with third-party-verified purity documentation.

References

  1. Coskun T, Urva S, Roell WC, Qu H, Loghin C, Moyers JS, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234-1247.e9. DOI: 10.1016/j.cmet.2022.07.013

  2. Li W, Zhou Q, Cong Z, Yuan Q, Li W, Zhao F, et al. Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. Cell Discov. 2024;10:77. PMID: 39019866. DOI: 10.1038/s41421-024-00700-0

  3. Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, et al. Triple–hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med. 2023;389(6):514-526. PMID: 37366315. DOI: 10.1056/NEJMoa2301972

  4. Rosenstock J, Frías JP, Jastreboff AM, Du Y, Lou J, Gurbuz S, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529-544. DOI: 10.1016/S0140-6736(23)01053-X

  5. ClinicalTrials.gov. A study of retatrutide (LY3437943) in participants who have obesity or overweight (TRIUMPH-1). NCT05929066. Available at: https://clinicaltrials.gov/study/NCT05929066

  6. ClinicalTrials.gov. A study of retatrutide (LY3437943) in participants with type 2 diabetes mellitus who have obesity or overweight. NCT05929079. Available at: https://clinicaltrials.gov/study/NCT05929079

  7. ClinicalTrials.gov. Effect of retatrutide compared with placebo in adult participants with type 2 diabetes and inadequate glycemic control with diet and exercise alone (TRANSCEND-T2D-1). NCT06354660. Available at: https://clinicaltrials.gov/study/NCT06354660

  8. The Lancet. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. Lancet. 2026. DOI: 10.1016/S0140-6736(26)00967-0

Frequently asked questions

  • What is retatrutide?

    Retatrutide (LY3437943) is a synthetic acylated peptide developed by Eli Lilly and Company, classified in the scientific literature as a simultaneous agonist at the glucose-dependent insulinotropic polypeptide receptor (GIPR), the glucagon-like peptide-1 receptor (GLP-1R), and the glucagon receptor (GCGR). This triple receptor engagement distinguishes it from selective GLP-1 receptor agonists and from dual GIP/GLP-1 receptor agonists such as tirzepatide.

  • What is the chemical structure of retatrutide?

    Retatrutide is an acylated synthetic peptide whose primary sequence was derived from the native human GIP peptide backbone. It incorporates sequence modifications and a fatty acid acyl chain attached via a linker to confer albumin-binding properties, which extends plasma half-life and enables extended-interval dosing consistent with other approved incretin agents.

  • Is retatrutide FDA approved?

    Retatrutide has not received regulatory approval from the FDA, the European Medicines Agency, or any comparable regulatory body for any therapeutic indication. It is classified as an investigational new drug in active clinical development by Eli Lilly under the TRIUMPH and TRANSCEND phase 3 trial programs.

  • Who developed retatrutide?

    Retatrutide was developed by Eli Lilly and Company as an extension of their tirzepatide research program. The compound designated LY3437943 was first described in the peer-reviewed literature by Coskun, Urva, Roell, and colleagues in Cell Metabolism in 2022.

  • What pharmacological class does retatrutide belong to?

    Retatrutide is classified as a triple GIP receptor, GLP-1 receptor, and glucagon receptor agonist — also referred to in the literature as a triagonist or triple incretin receptor agonist. This classification distinguishes it from selective GLP-1 receptor agonists such as semaglutide and from dual GIP/GLP-1 receptor agonists such as tirzepatide.